Maze Therapeutics, Inc. (MAZE)
NASDAQ: MAZE · Real-Time Price · USD
32.00
-0.11 (-0.33%)
Oct 29, 2025, 1:09 PM EDT - Market open
Maze Therapeutics Revenue
Maze Therapeutics had revenue of $2.50M in the twelve months ending June 30, 2025, down -98.48% year-over-year. In the year 2024, Maze Therapeutics had annual revenue of $167.50M.
Revenue (ttm)
$2.50M
Revenue Growth
-98.48%
P/S Ratio
248.35
Revenue / Employee
$20,000
Employees
125
Market Cap
1.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 167.50M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionMAZE News
- 1 day ago - San Francisco is making a comeback. So are these stocks from the City by the Bay - CNBC
- 23 days ago - Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors - GlobeNewsWire
- 6 weeks ago - Maze Therapeutics, Inc. (MAZE) Discuses On MZE782 Phase 1 Healthy Volunteer Trial Results Call (Transcript) - Seeking Alpha
- 6 weeks ago - Maze Shares Jump As Investors Bet Big On Experimental Treatment's Potential - Benzinga
- 6 weeks ago - Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement - GlobeNewsWire
- 6 weeks ago - Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) - GlobeNewsWire
- 2 months ago - Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer - GlobeNewsWire
- 2 months ago - National Advertising Division Refers Maze Therapeutics to Regulatory Authorities for Failure to Respond to Inquiry - GlobeNewsWire